Attached files
| file | filename |
|---|---|
| 8-K/A - 8-K/A - Mallinckrodt plc | mnk8-ka041715041515.htm |
| EX-23.1 - EXHIBIT 23.1 - Mallinckrodt plc | mnkexhibit231consentikaria.htm |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
The following unaudited pro forma combined financial information is presented to illustrate the estimated effects of (i) the acquisition of Compound Holdings II, Inc. ("Compound Holdings II"), the sole stockholder of Ikaria, Inc., ("Ikaria") by Mallinckrodt plc, including, unless the context requires otherwise, its consolidated subsidiaries, ("Mallinckrodt" or "the Company"), which was completed on April 16, 2015 (the "Ikaria Acquisition"), (ii) the acquisition of Questcor Pharmaceuticals Inc. ("Questcor") by Mallinckrodt, which was completed on August 14, 2014, (iii) the acquisition of Cadence Pharmaceuticals, Inc. ("Cadence") by Mallinckrodt, which was completed on March 19, 2014, (iv) the related financings to fund the foregoing transactions and (v) the related tax effects from the foregoing transactions.
The fiscal year of Mallinckrodt ends on the last Friday in September and the fiscal years of Ikaria, Questcor and Cadence end on December 31. The following unaudited pro forma condensed combined statement of income for the fiscal year ended September 26, 2014 was prepared based on the following historical periods: (i) the historical consolidated statement of income of Mallinckrodt for the fiscal year ended September 26, 2014, (ii) the historical condensed statement of operations of Cadence for the three months ended December 31, 2013, which was derived by subtracting the condensed statement of operations for the nine months ended September 30, 2013 from the statement of operations for the fiscal year ended December 31, 2013, (iii) the unaudited financial information of Cadence for the period January 1, 2014 to March 18, 2014, (iv) the historical consolidated condensed statement of income of Questcor for the three months ended December 31, 2013, which was derived by subtracting the consolidated condensed statement of income for the nine months ended September 30, 2013 from the consolidated statement of income for the fiscal year ended December 31, 2013, (v) the historical consolidated condensed statement of income of Questcor for the six months ended June 30, 2014, (vi) the unaudited financial information of Questcor for the period July 1, 2014 to August 14, 2014, and (vii) the Ikaria unaudited pro forma condensed combined statement of operations for the year ended September 30, 2014.
The following unaudited pro forma condensed combined statement of income for the three months ended December 26, 2014 was prepared based on the following historical periods: (i) the historical condensed consolidated statement of income of Mallinckrodt for the three months ended December 26, 2014 and (ii) the Ikaria unaudited pro forma condensed combined statement of operations for the three months ended December 26, 2014.
The following unaudited pro forma condensed combined balance sheet was prepared based on the following historical dates: (i) the historical condensed consolidated balance sheet of Mallinckrodt as of December 26, 2014, which includes balances related to Cadence, following the completion of the acquisition of Cadence on March 19, 2014, and Questcor, following the completion of the acquisition of Questcor on August 14, 2014, and (ii) the historical condensed consolidated balance sheet of Compound Holdings II as of December 31, 2014.
For further information on the historical financial information of Cadence and Questcor refer to Notes 4 and 5, respectively, of the accompanying notes to the unaudited pro forma condensed combined financial statements.
The following Ikaria unaudited pro forma combined financial information is presented to illustrate the effects of (i) the acquisition of Ikaria by Compound Holdings II on February 12, 2014, (ii) the distribution of Ikaria's research and development business, Bellerophon Therapeutics LLC to existing Ikaria stockholders ("Bellerophon Spin-Out") on February 12, 2014, and (iii) the related tax effects from the foregoing transactions.
The following Ikaria unaudited pro forma condensed combined statement of operations for the fiscal year ended December 31, 2014 was prepared based on the following historical periods: (i) the historical consolidated condensed statement of operations of Ikaria for the predecessor period ended February 11, 2014 and (ii) the historical consolidated condensed statement of operations of Compound Holdings II for the successor period ended December 31, 2014.
The following Ikaria unaudited pro forma condensed combined statement of operations for the three months ended December 31, 2014 was prepared based on the unaudited financial information for the three months ended December 31, 2014.
The following Ikaria unaudited pro forma condensed combined statement of operations for the three months ended December 31, 2013 was prepared based on the condensed combined statement of operations for the three months ended December 31, 2013, which was derived by subtracting the condensed combined statement of operations for the nine months ended September 30, 2013 from the condensed combined statements of operations for the fiscal year ended December 31, 2013.
For further information on the historical financial information and unaudited pro forma financial information of Ikaria, refer to Note 6 of the accompanying notes to the unaudited pro forma condensed combined financial statements.
The pro forma adjustments are preliminary and are based upon available information and certain assumptions, described in the accompanying notes to the unaudited pro forma combined financial information that management believes are
1
reasonable under the circumstances. Actual results may differ materially from the unaudited pro forma combined financial information (including the assumptions within the accompanying unaudited pro forma combined financial information).
The following unaudited pro forma condensed combined financial information has been prepared to reflect the acquisitions of Cadence, Questcor and Ikaria and the related financings and is provided for informational purposes only. The unaudited pro forma condensed combined statements of income assume that the aforementioned transactions occurred on September 28, 2013. The unaudited pro forma condensed combined statements of income are not necessarily indicative of operating results that would have been achieved had the acquisitions of Cadence, Questcor and Ikaria occurred on September 28, 2013, nor is it intended to project the future financial results of Mallinckrodt after the acquisitions. The unaudited pro forma condensed combined balance sheet assumes that the Ikaria Acquisition was completed on December 26, 2014. The unaudited pro forma condensed combined balance sheet does not necessarily reflect what Mallinckrodt’s financial position would have been had the Ikaria Acquisition been completed on December 26, 2014, or for any future or historical period.
The unaudited pro forma condensed combined financial information has been prepared using certain assumptions, as described in the accompanying notes, which management believes are reasonable and do not reflect the cost of any integration activities, benefits from any synergies that may be derived from the acquisitions of Cadence, Questcor and Ikaria or revenue growth that may be anticipated. These unaudited pro forma condensed combined financial statements and related notes should be read in conjunction with the historical financial statements and related notes of Mallinckrodt, Cadence and Questcor included in their Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC and the the historical financial statements and related notes of Compound Holdings II and Ikaria incorporated by reference from the Company's Current Report on Form 8-K filed on April 6, 2015.
2
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF INCOME
For the Fiscal Year Ended September 26, 2014
(in millions, except per share data)
Historical Mallinckrodt | Historical Cadence | Cadence Acquisition Pro Forma Adjustments | Mallinckrodt Subtotal After Cadence Acquisition | Historical Questcor | Questcor Acquisition Pro Forma Adjustments | Mallinckrodt Subtotal After Questcor Acquisition | Pro Forma Ikaria | Ikaria Acquisition Pro Forma Adjustments | Pro Forma | ||||||||||||||||||||||||||||||
Net sales | $ | 2,540.4 | $ | 65.7 | $ | — | $ | 2,606.1 | $ | 881.1 | $ | — | $ | 3,487.2 | $ | 402.8 | $ | — | $ | 3,890.0 | |||||||||||||||||||
Cost of sales | 1,337.3 | 22.0 | 62.4 | a,b, c | 1,421.7 | 76.4 | 240.2 | h,i | 1,738.3 | 54.0 | 110.7 | o | 1,903.0 | ||||||||||||||||||||||||||
Gross profit | 1,203.1 | 43.7 | (62.4 | ) | 1,184.4 | 804.7 | (240.2 | ) | 1,748.9 | 348.8 | (110.7 | ) | 1,987.0 | ||||||||||||||||||||||||||
Selling, general and administrative expenses | 842.1 | 73.1 | (45.2 | ) | c,d, e | 870.0 | 294.8 | (91.7 | ) | j,k | 1,073.1 | 155.9 | (60.5 | ) | o | 1,168.5 | |||||||||||||||||||||||
Research and development expenses | 166.9 | 3.4 | — | 170.3 | 73.8 | — | 244.1 | 41.3 | — | 285.4 | |||||||||||||||||||||||||||||
Separation costs | 9.6 | — | — | 9.6 | — | — | 9.6 | — | — | 9.6 | |||||||||||||||||||||||||||||
Restructuring charges, net | 128.6 | — | — | 128.6 | — | — | 128.6 | — | — | 128.6 | |||||||||||||||||||||||||||||
Non-restructuring impairments | 355.6 | — | — | 355.6 | — | — | 355.6 | — | — | 355.6 | |||||||||||||||||||||||||||||
Gains on divestiture and license | (15.6 | ) | — | — | (15.6 | ) | — | — | (15.6 | ) | — | — | (15.6 | ) | |||||||||||||||||||||||||
Operating income (loss) | (284.1 | ) | (32.8 | ) | (17.2 | ) | (334.1 | ) | 436.1 | (148.5 | ) | (46.5 | ) | 151.6 | (50.2 | ) | 54.9 | ||||||||||||||||||||||
Interest expense | (82.6 | ) | (2.3 | ) | (21.6 | ) | f | (106.5 | ) | — | (72.5 | ) | l | (179.0 | ) | (84.6 | ) | 1.5 | p | (262.1 | ) | ||||||||||||||||||
Interest income | 1.5 | — | — | 1.5 | — | — | 1.5 | 0.3 | — | 1.8 | |||||||||||||||||||||||||||||
Other (expense) income, net | 1.8 | — | — | 1.8 | (0.6 | ) | — | 1.2 | — | — | 1.2 | ||||||||||||||||||||||||||||
Income (loss) from continuing operations before income taxes | (363.4 | ) | (35.1 | ) | (38.8 | ) | (437.3 | ) | 435.5 | (221.0 | ) | (222.8 | ) | 67.3 | (48.7 | ) | (204.2 | ) | |||||||||||||||||||||
Provision for income taxes | (44.8 | ) | — | (38.5 | ) | g | (83.3 | ) | 150.9 | 36.8 | m | 104.4 | 33.4 | (24.9 | ) | q | 112.9 | ||||||||||||||||||||||
Income (loss) from continuing operations | $ | (318.6 | ) | $ | (35.1 | ) | $ | (0.3 | ) | $ | (354.0 | ) | $ | 284.6 | $ | (257.8 | ) | $ | (327.2 | ) | $ | 33.9 | $ | (23.8 | ) | $ | (317.1 | ) | |||||||||||
Basic earnings (loss) per share from continuing operations: | |||||||||||||||||||||||||||||||||||||||
Basic | $ | (4.91 | ) | $ | (5.45 | ) | $ | (2.87 | ) | $ | (2.77 | ) | |||||||||||||||||||||||||||
Diluted | $ | (4.91 | ) | $ | (5.45 | ) | $ | (2.87 | ) | $ | (2.77 | ) | |||||||||||||||||||||||||||
Weighted-average shares outstanding: | |||||||||||||||||||||||||||||||||||||||
Basic | 64.9 | 64.9 | 49.1 | n | 114.0 | 114.0 | |||||||||||||||||||||||||||||||||
Diluted | 64.9 | 64.9 | 49.1 | n | 114.0 | 114.0 | |||||||||||||||||||||||||||||||||
See Notes to Unaudited Pro Forma Condensed Combined Financial Statements.
3
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF INCOME
For the Three Months Ended December 26, 2014
(in millions, except per share data)
Historical Mallinckrodt | Pro Forma Ikaria | Ikaria Acquisition Pro Forma Adjustments | Pro Forma | ||||||||||||
Net sales | $ | 866.3 | $ | 101.3 | $ | — | $ | 967.6 | |||||||
Cost of sales | 427.6 | 15.0 | 27.7 | o | 470.3 | ||||||||||
Gross profit | 438.7 | 86.3 | (27.7 | ) | 497.3 | ||||||||||
Selling, general and administrative expenses | 262.5 | 45.6 | (15.2 | ) | o | 292.9 | |||||||||
Research and development expenses | 42.4 | 12.1 | — | 54.5 | |||||||||||
Separation costs | — | — | — | — | |||||||||||
Restructuring charges, net | 7.2 | — | — | 7.2 | |||||||||||
Non-restructuring impairments | — | — | — | — | |||||||||||
Gains on divestiture and license | (0.8 | ) | — | — | (0.8 | ) | |||||||||
Operating income (loss) | 127.4 | 28.6 | (12.5 | ) | 143.5 | ||||||||||
Interest expense | (48.8 | ) | (19.8 | ) | (1.0 | ) | p | (69.6 | ) | ||||||
Interest income | 0.1 | — | — | 0.1 | |||||||||||
Other (expense) income, net | 4.1 | — | — | 4.1 | |||||||||||
Income (loss) from continuing operations before income taxes | 82.8 | 8.8 | (13.5 | ) | 78.1 | ||||||||||
Provision for income taxes | (9.3 | ) | 4.0 | (6.7 | ) | q | (12.0 | ) | |||||||
Income (loss) from continuing operations | $ | 92.1 | $ | 4.8 | $ | (6.8 | ) | $ | 90.1 | ||||||
Basic earnings (loss) per share from continuing operations: | |||||||||||||||
Basic | $ | 0.79 | $ | 0.78 | |||||||||||
Diluted | $ | 0.78 | $ | 0.77 | |||||||||||
Weighted-average shares outstanding: | |||||||||||||||
Basic | 114.8 | 114.8 | |||||||||||||
Diluted | 116.3 | 116.3 | |||||||||||||
See Notes to Unaudited Pro Forma Condensed Combined Financial Statements.
4
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET
As of December 26, 2014
(in millions)
Historical Mallinckrodt | Historical Compound Holdings II, Inc. | Ikaria Acquisition Pro Forma Adjustments | Pro Forma | ||||||||||||
Assets | |||||||||||||||
Current Assets: | |||||||||||||||
Cash and cash equivalents | $ | 899.0 | $ | 98.9 | $ | (704.8 | ) | a | $ | 293.1 | |||||
Accounts receivable, net | 508.5 | 64.6 | — | 573.1 | |||||||||||
Inventories | 369.3 | 51.6 | (11.6 | ) | b | 409.3 | |||||||||
Deferred income taxes | 146.4 | 12.0 | 4.4 | c | 162.8 | ||||||||||
Prepaid expenses and other current assets | 141.8 | 20.2 | — | 162.0 | |||||||||||
Total current assets | 2,065.0 | 247.3 | (712.0 | ) | 1,600.3 | ||||||||||
Property, plant and equipment, net | 945.6 | 64.1 | — | 1,009.7 | |||||||||||
Goodwill | 2,413.7 | 457.9 | 283.2 | d | 3,154.8 | ||||||||||
Intangible assets, net | 6,984.9 | 969.5 | 1,000.5 | e | 8,954.9 | ||||||||||
Other assets | 364.4 | 32.1 | (6.4 | ) | f | 390.1 | |||||||||
Total Assets | $ | 12,773.6 | $ | 1,770.9 | $ | 565.3 | $ | 15,109.8 | |||||||
Liabilities and Shareholders' Equity | |||||||||||||||
Current Liabilities: | |||||||||||||||
Current maturities of long-term debt | $ | 22.9 | $ | 69.8 | $ | (69.8 | ) | f | $ | 22.9 | |||||
Accounts payable | 122.4 | 12.3 | — | 134.7 | |||||||||||
Accrued and other current liabilities | 619.7 | 43.1 | — | 662.8 | |||||||||||
Total current liabilities | 765.0 | 125.2 | (69.8 | ) | 820.4 | ||||||||||
Long-term debt | 3,942.2 | 1,092.3 | 547.7 | f | 5,582.2 | ||||||||||
Pension and other postretirement benefits | 116.2 | — | — | 116.2 | |||||||||||
Environmental liabilities | 62.0 | — | — | 62.0 | |||||||||||
Deferred income taxes | 2,344.1 | 278.3 | 382.2 | c | 3,004.6 | ||||||||||
Other liabilities | 472.3 | 0.5 | — | 472.8 | |||||||||||
Total Liabilities | 7,701.8 | 1,496.3 | 860.1 | 10,058.2 | |||||||||||
Shareholders' Equity: | |||||||||||||||
Preferred shares | — | — | — | — | |||||||||||
Ordinary shares | 23.3 | — | — | 23.3 | |||||||||||
Ordinary shares held in treasury at cost | (28.1 | ) | — | — | (28.1 | ) | |||||||||
Additional paid-in capital | 5,225.3 | 414.6 | (414.6 | ) | g | 5,225.3 | |||||||||
Retained earnings (accumulated deficit) | (193.1 | ) | (139.8 | ) | 119.8 | g, h | (213.1 | ) | |||||||
Accumulated other comprehensive income | 44.4 | (0.2 | ) | — | 44.2 | ||||||||||
Total Shareholders' Equity | 5,071.8 | 274.6 | (294.8 | ) | 5,051.6 | ||||||||||
Total Liabilities and Shareholders' Equity | $ | 12,773.6 | $ | 1,770.9 | $ | 565.3 | $ | 15,109.8 | |||||||
See the accompanying Notes to Unaudited Pro Forma Condensed Combined Financial Statements.
5
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
(dollars in millions, except per share data and where indicated)
1. | Description of Transactions |
Ikaria Acquisition. On April 16, 2015, Mallinckrodt acquired all of the outstanding common stock of Compound Holdings II, the sole stockholder of Ikaria, a fully-integrated biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed for the critical care market, in a transaction valued at approximately $2.3 billion, net of cash acquired. Consideration for the transaction consisted of approximately $1.2 billion in cash paid to Compound Holdings II shareholders and the assumption of approximately $1.1 billion of Ikaria third-party debt, which was repaid in conjunction with the Ikaria Acquisition. The acquisition and repayment of debt was primarily funded through the issuance of $1.4 billion aggregate principal amount of senior unsecured notes, a $240.0 million borrowing under the revolver and cash on hand. The Ikaria Acquisition is expected to provide a platform for future revenue and earnings growth within Mallinckrodt’s Specialty Brands segment.
Questcor Acquisition. On August 14, 2014, the Company acquired all of the outstanding common stock of Questcor, a biopharmaceutical company, for total consideration of approximately $5.9 billion, comprised of cash consideration of $30.00 per share, 0.897 ordinary shares of the Company for each share of Questcor common stock owned and the portion of outstanding equity awards deemed to have been earned as of August 14, 2014. The acquisition was funded through an issuance of approximately 57 million common shares, proceeds from the issuance of $900.0 million aggregate principle amount of senior unsecured notes, proceeds from a $700.0 million senior secured term loan facility, $150.0 million of cash from a receivable securitization program and cash on hand. Acthar ® Gel (repository corticotropin injection), Questcor’s primary product, is focused on the treatment of patients with serious, difficult-to-treat autoimmune and rare diseases. Acthar is an injectable drug that is approved by the U.S. Food and Drug Administration for use in 19 indications, including the areas of neurology, rheumatology, nephrology and pulmonology. Questcor also supplies specialty contract manufacturing services to the pharmaceutical and biotechnology industry through its wholly-owned subsidiary, Bio-Vectra, Inc.
Cadence Acquisition. On March 19, 2014, Mallinckrodt acquired all of the outstanding common stock of Cadence, a biopharmaceutical company focused on commercializing products principally for use in the hospital setting, for $14.00 per share in cash, or a total consideration of approximately $1.3 billion. The Cadence acquisition was primarily funded through a $1.3 billion senior secured term loan credit facility. Cadence’s sole product, OFIRMEV, is a proprietary intravenous formulation of acetaminophen for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever. The Cadence acquisition added a growth product to Mallinckrodt’s Specialty Brands product portfolio and provided Mallinckrodt an opportunity to expand its reach into the adjacent hospital market, in which Cadence has established a strong presence.
2. | Basis of Pro Forma Presentation |
The unaudited pro forma condensed combined financial statements are based on the historical financial information of Mallinckrodt, Questcor and Cadence as previously provided in or derived from the respective company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC and the historical financial statements of Compound Holdings II and Ikaria, described further in Note 6. The unaudited pro forma condensed combined statements of income for the fiscal year ended September 26, 2014 and the three months ended December 26, 2014 assume that the acquisitions of Cadence, Questcor and Ikaria and the related financings occurred on September 28, 2013. The unaudited pro forma condensed combined balance sheet as of December 26, 2014 assumes that the Ikaria Acquisition occurred on December 26, 2014.
The pro forma adjustments reflected in the unaudited pro forma condensed combined statements of income are based on items that are (i) directly attributable to the Ikaria, Questcor and Cadence acquisitions and the related financings, (ii) factually supportable and (iii) expected to have a continuing impact on the results of operations of Mallinckrodt. The pro forma adjustments reflected in the unaudited pro forma condensed combined balance sheet are based on items that are directly attributable to the Ikaria Acquisition and related financing and are factually supportable. The pro forma adjustments are preliminary and are based upon available information and certain assumptions, as described further in Note 3, Note 7 and Note 8, that management believes are reasonable. Actual results may differ from the information presented by the unaudited pro forma condensed combined financial statements (including the assumptions contained within the unaudited pro forma condensed combined financial statements).
6
The acquisitions of Cadence, Questcor and Ikaria have been accounted for using the acquisition method of accounting, with Mallinckrodt identified as the acquirer. Under the acquisition method of accounting, Mallinckrodt records all assets acquired and liabilities assumed at their respective acquisition-date fair values. The excess purchase price over the amounts assigned to tangible or intangible assets acquired and liabilities assumed is recognized as goodwill. At this time, the valuation analysis and calculations necessary to arrive at the final estimates of the fair market value of Questcor and Ikaria assets acquired and liabilities assumed have not yet been finalized. As such, the assets and liabilities presented within the unaudited pro forma condensed combined financial information should be treated as preliminary values, and actual results may differ materially from the information presented. Additionally, this unaudited pro forma condensed combined financial information does not reflect the cost of any integration activities, benefits from any synergies that may be derived from the Ikaria, Questcor and Cadence acquisitions or revenue growth that may be anticipated, all of which may have a material impact on Mallinckrodt’s results of operations following the acquisitions.
3. | Ikaria Purchase Price Allocation |
The preliminary estimate of the Ikaria purchase price was determined as follows:
Cash consideration | $ | 2,300.0 | |
Debt assumed | (1,162.1 | ) | |
Total consideration | $ | 1,137.9 | |
The following preliminary allocation of the Ikaria purchase price is based on Mallinckrodt’s preliminary estimates of the fair value of the tangible and intangible assets and liabilities of Ikaria, and was prepared using the historical book value of Ikaria assets and liabilities as of December 31, 2014. The final determination of the allocation of the purchase price will be based on the fair value of such assets and liabilities as of the date that the Ikaria Acquisition is completed. At this time, the valuation analysis and calculations necessary to arrive at the final estimates of the fair market value of Ikaria assets acquired and liabilities assumed have not yet been finalized. As such, the final determination of the purchase price allocation may be materially different than the preliminary estimates used in this unaudited pro forma condensed combined financial information.
Total consideration | $ | 1,137.9 | |
Allocated to: | |||
Cash and cash equivalents | $ | 98.9 | |
Inventory | 40.0 | ||
Intangible assets | 1,970.0 | ||
Goodwill | 741.1 | ||
Other assets | 149.8 | ||
Deferred tax liabilities, net | (644.1 | ) | |
Other liabilities | (55.9 | ) | |
Long-term debt | (1,162.1 | ) | |
Accumulated other comprehensive income | 0.2 | ||
Net assets acquired | $ | 1,137.9 | |
4. | Historical Cadence |
The financial information presented in the “Historical Cadence” column of the unaudited pro forma condensed combined statement of income for the fiscal year ended September 26, 2014 represents the historical condensed statement of operations of Cadence for the three months ended December 31, 2013, which was derived by subtracting the condensed statement of operations for the nine months ended September 30, 2013 from the statement of operations for the fiscal year ended December 31, 2013, and adding the unaudited financial information for the period January 1, 2014 to March 18, 2014. The chart below depicts the calculation of the “Historical Cadence” columns outlined above, as follows:
7
Year Ended December 31, 2013 | Nine Months Ended September 30, 2013 | Three Months Ended December 31, 2013 | January 1, 2014 to March 18, 2014 | October 1, 2013 to March 18, 2014 | |||||||||||||||
Revenues: | |||||||||||||||||||
Product revenue, net | $ | 110.5 | $ | 77.2 | $ | 33.3 | $ | 30.4 | $ | 63.7 | |||||||||
License revenue | 2.0 | — | 2.0 | — | 2.0 | ||||||||||||||
Total net revenues | 112.5 | 77.2 | 35.3 | 30.4 | 65.7 | ||||||||||||||
Costs and expenses: | |||||||||||||||||||
Cost of product sales | 37.9 | 26.3 | 11.6 | 9.8 | 21.4 | ||||||||||||||
Amortization of patent license | 1.3 | 1.0 | 0.3 | 0.3 | 0.6 | ||||||||||||||
Research and development | 6.7 | 4.7 | 2.0 | 1.4 | 3.4 | ||||||||||||||
Selling, general and administrative | 94.5 | 70.3 | 24.2 | 48.7 | 72.9 | ||||||||||||||
Other | (0.4 | ) | (0.6 | ) | 0.2 | — | 0.2 | ||||||||||||
Total costs and expenses | 140.0 | 101.7 | 38.3 | 60.2 | 98.5 | ||||||||||||||
Loss from operations | (27.5 | ) | (24.5 | ) | (3.0 | ) | (29.8 | ) | (32.8 | ) | |||||||||
Other income (expense): | |||||||||||||||||||
Interest income | 0.1 | 0.1 | — | — | — | ||||||||||||||
Interest expense | (4.4 | ) | (3.3 | ) | (1.1 | ) | (1.2 | ) | (2.3 | ) | |||||||||
Other income | 7.6 | 7.6 | — | — | — | ||||||||||||||
Total other income (expense), net | 3.3 | 4.4 | (1.1 | ) | (1.2 | ) | (2.3 | ) | |||||||||||
Loss before income tax | (24.2 | ) | (20.1 | ) | (4.1 | ) | (31.0 | ) | (35.1 | ) | |||||||||
Net loss | $ | (24.2 | ) | $ | (20.1 | ) | $ | (4.1 | ) | $ | (31.0 | ) | $ | (35.1 | ) | ||||
To conform with Mallinckrodt's presentation, amortization of patent license has been included in cost of sales and other expense has been included within selling, general and administrative expense in the unaudited pro forma condensed combined statement of income.
The results of Cadence from and after the acquisition date of March 19, 2014 are included within the "Historical Mallinckrodt" column of the unaudited pro condensed combined statement of income for the three months ended December 26, 2014. As Cadence was included within the historical financial position of Mallinckrodt as of December 26, 2014, the unaudited pro forma condensed combined balance sheet as of December 26, 2014 does not include separate Cadence financial information.
5. | Historical Questcor |
The financial information presented in the “Historical Questcor” column of the unaudited pro forma condensed combined statement of income for the fiscal year ended September 26, 2014 represents the historical condensed statement of operations of Questcor for the three months ended December 31, 2013, which was derived by subtracting the condensed statement of operations for the nine months ended September 30, 2013 from the condensed statement of operations for the fiscal year ended December 31, 2013, adding the condensed statement of operations for the six months ended June 30, 2014 and adding the unaudited financial information for the period July 1, 2014 to August 14, 2014. The chart below depicts the calculation of the “Historical Questcor” columns outlined above, as follows:
8
Year Ended December 31, 2013 | Nine Months Ended September 30, 2013 | Three Months Ended December 31, 2013 | Six Months Ended June 30, 2014 | July 1, 2014 to August 14, 2014 | October 1, 2013 to August 14, 2014 | ||||||||||||||||||
Revenue | |||||||||||||||||||||||
Pharmaceutical net sales | $ | 761.3 | $ | 531.1 | $ | 230.2 | $ | 471.2 | $ | 127.4 | $ | 828.8 | |||||||||||
Contract manufacturing net sales | 37.6 | 24.9 | 12.7 | 34.8 | 4.8 | 52.3 | |||||||||||||||||
Total net sales | 798.9 | 556.0 | 242.9 | 506.0 | 132.2 | 881.1 | |||||||||||||||||
Cost of sales (exclusive of amortization of purchased technology) | 74.3 | 53.4 | 20.9 | 44.6 | 10.9 | 76.4 | |||||||||||||||||
Gross profit | 724.6 | 502.6 | 222.0 | 461.4 | 121.3 | 804.7 | |||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Selling and marketing | 153.0 | 114.1 | 38.9 | 103.9 | 24.0 | 166.8 | |||||||||||||||||
General and administrative | 56.4 | 41.1 | 15.3 | 49.5 | 47.7 | 112.5 | |||||||||||||||||
Research and development | 59.7 | 40.1 | 19.6 | 41.9 | 12.3 | 73.8 | |||||||||||||||||
Depreciation and amortization | 4.1 | 3.1 | 1.0 | 2.1 | 0.5 | 3.6 | |||||||||||||||||
Change in fair value of contingent consideration | 9.8 | 1.3 | 8.5 | 2.4 | 1.0 | 11.9 | |||||||||||||||||
Impairment of goodwill and intangibles | 0.7 | 0.7 | — | — | — | — | |||||||||||||||||
Total operating expenses | 283.7 | 200.4 | 83.3 | 199.8 | 85.5 | 368.6 | |||||||||||||||||
Income from operations | 440.9 | 302.2 | 138.7 | 261.6 | 35.8 | 436.1 | |||||||||||||||||
Interest and other income, net | (1.0 | ) | (1.0 | ) | — | (1.0 | ) | 0.5 | (0.5 | ) | |||||||||||||
Foreign currency transaction loss | (0.5 | ) | (0.5 | ) | — | (0.1 | ) | — | (0.1 | ) | |||||||||||||
Income before income taxes | 439.4 | 300.7 | 138.7 | 260.5 | 36.3 | 435.5 | |||||||||||||||||
Income tax expense | 146.9 | 98.1 | 48.8 | 89.8 | 12.3 | 150.9 | |||||||||||||||||
Net income | $ | 292.5 | $ | 202.6 | $ | 89.9 | $ | 170.7 | $ | 24.0 | $ | 284.6 | |||||||||||
To conform with Mallinckrodt's presentation, impairment of goodwill and intangibles has been included in cost of sales and selling and marketing, general and administrative, depreciation and amortization and change in fair value of contingent consideration have been included within selling, general and administrative expense in the unaudited pro forma condensed combined statement of income.
The results of Questcor from and after the acquisition date of August 14, 2014 are included within the "Historical Mallinckrodt" column of the unaudited pro forma condensed combined statement of income for the three months ended December 26, 2014. As Questcor was included within the historical financial position of Mallinckrodt as of December 26, 2014, the unaudited pro forma condensed combined balance sheet as of December 26, 2014 does not include separate Questcor financial information.
6. | Historical Ikaria |
Financial information presented in the "Pro Forma Ikaria" column of the unaudited pro forma condensed combined statement of income for the fiscal year ended September 26, 2014 represents the pro forma historical statement of operations of Ikaria for the twelve months ended September 30, 2014, which was derived by subtracting the unaudited pro forma condensed combined statement of operations for the three months ended December 31, 2014 from the unaudited pro forma condensed combined statement of operations for the fiscal year ended December 31, 2014, and adding the unaudited pro forma condensed combined statement of operations for the three months ended December 31, 2013 as follows:
9
UNAUDITED IKARIA PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
For the Year Ended September 30, 2014
(in millions)
Pro Forma Ikaria Year Ended December 31, 2014 | Pro Forma Ikaria Three Months Ended December 31, 2014 | Pro Forma Ikaria Three Months Ended December 31, 2013 | Pro Forma Ikaria Year Ended September 30, 204 | ||||||||||||
Revenues: | |||||||||||||||
Net Sales | $ | 395.1 | $ | 96.1 | $ | 93.3 | $ | 392.3 | |||||||
Sales to related parties | 10.8 | 5.2 | 4.9 | 10.5 | |||||||||||
Total revenues | 405.9 | 101.3 | 98.2 | 402.8 | |||||||||||
Operating expenses: | |||||||||||||||
Cost of sales | 54.8 | 15.0 | 14.2 | 54.0 | |||||||||||
Selling, general and administrative expenses | 91.6 | 30.7 | 32.6 | 93.5 | |||||||||||
Research and development expenses | 37.4 | 12.1 | 16.0 | 41.3 | |||||||||||
Amortization of acquired intangibles | 65.1 | 16.4 | 16.3 | 65.0 | |||||||||||
Merger transaction costs and expenses | — | — | — | — | |||||||||||
Other operating (income) expense, net | (5.3 | ) | (1.5 | ) | 1.2 | (2.6 | ) | ||||||||
Income from operations | 162.3 | 28.6 | 17.9 | 151.6 | |||||||||||
Other (expense) income: | |||||||||||||||
Interest income | 0.1 | — | 0.2 | 0.3 | |||||||||||
Interest expense | (81.3 | ) | (19.8 | ) | (23.1 | ) | (84.6 | ) | |||||||
Loss on extinguishment of debt | — | — | — | — | |||||||||||
(Loss) income before income taxes | 81.1 | 8.8 | (5.0 | ) | 67.3 | ||||||||||
Income tax (benefit) expense | 30.8 | 4.0 | 6.6 | 33.4 | |||||||||||
Net income (loss) | $ | 50.3 | $ | 4.8 | $ | (11.6 | ) | $ | 33.9 | ||||||
To conform with Mallinckrodt's presentation, amortization of acquired intangibles and other operating (income) expense, net have been included within selling, general and administrative expense in the unaudited pro forma condensed combined statement of income.
10
The following Ikaria unaudited pro forma condensed combined statement of operations for the fiscal year ended December 31, 2014 was prepared based on the following historical periods: (i) the historical consolidated condensed statement of operations of Ikaria for the predecessor period ended February 11, 2014 and (ii) the historical consolidated condensed statement of operations of Compound Holdings II for the successor period ended December 31, 2014.
UNAUDITED IKARIA PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
For the Year Ended December 31, 2014
(in millions)
Ikaria Period Ended February 11, 2014 | Compound Holdings II Period Ended December 31, 2014 | Combined Ikaria Year Ended December 31, 2014 | Pro Forma Adjustments | Pro Forma Ikaria Year Ended December 31, 2014 | |||||||||||||||
Revenues: | |||||||||||||||||||
Net Sales | $ | 47.9 | $ | 347.2 | $ | 395.1 | $ | — | $ | 395.1 | |||||||||
Sales to related parties | 0.3 | 10.5 | 10.8 | — | 10.8 | ||||||||||||||
Total revenues | 48.2 | 357.7 | 405.9 | — | 405.9 | ||||||||||||||
Operating expenses: | |||||||||||||||||||
Cost of sales | 6.3 | 336.2 | 342.5 | (287.7 | ) | a | 54.8 | ||||||||||||
Selling, general and administrative expenses | 12.3 | 79.3 | 91.6 | — | 91.6 | ||||||||||||||
Research and development expenses | 8.6 | 29.9 | 38.5 | (1.1 | ) | b | 37.4 | ||||||||||||
Amortization of acquired intangibles | — | 57.5 | 57.5 | 7.6 | c | 65.1 | |||||||||||||
Merger transaction costs and expenses | 64.7 | 7.6 | 72.3 | (72.3 | ) | d | — | ||||||||||||
Other operating (income) expense, net | 0.3 | (5.6 | ) | (5.3 | ) | — | (5.3 | ) | |||||||||||
Income from operations | (44.0 | ) | (147.2 | ) | (191.2 | ) | 353.5 | 162.3 | |||||||||||
Other (expense) income: | |||||||||||||||||||
Interest income | — | 0.1 | 0.1 | — | 0.1 | ||||||||||||||
Interest expense | (9.5 | ) | (71.8 | ) | (81.3 | ) | — | (81.3 | ) | ||||||||||
Loss on extinguishment of debt | — | — | — | — | — | ||||||||||||||
(Loss) income before income taxes | (53.5 | ) | (218.9 | ) | (272.4 | ) | 353.5 | 81.1 | |||||||||||
Income tax (benefit) expense | (20.1 | ) | (81.4 | ) | (101.5 | ) | 132.3 | e | 30.8 | ||||||||||
Net income (loss) | $ | (33.4 | ) | $ | (137.5 | ) | $ | (170.9 | ) | $ | 221.2 | $ | 50.3 | ||||||
11
UNAUDITED IKARIA PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
For the Three Months Ended December 31, 2014
(in millions)
Compound Holdings II Three Months Ended December 31, 2014 | Pro Forma Adjustments | Pro Forma Ikaria Three Months Ended December 31, 2014 | |||||||||
Revenues: | |||||||||||
Net Sales | $ | 96.1 | $ | — | $ | 96.1 | |||||
Sales to related parties | 5.2 | — | 5.2 | ||||||||
Total revenues | 101.3 | — | 101.3 | ||||||||
Operating expenses: | |||||||||||
Cost of sales | 93.3 | (78.3 | ) | a | 15.0 | ||||||
Selling, general and administrative expenses | 30.7 | — | 30.7 | ||||||||
Research and development expenses | 12.1 | — | 12.1 | ||||||||
Amortization of acquired intangibles | 16.4 | — | 16.4 | ||||||||
Merger transaction costs and expenses | — | — | — | ||||||||
Other operating (income) expense, net | (1.5 | ) | — | (1.5 | ) | ||||||
Income from operations | (49.7 | ) | 78.3 | 28.6 | |||||||
Other (expense) income: | |||||||||||
Interest income | — | — | — | ||||||||
Interest expense | (19.8 | ) | — | (19.8 | ) | ||||||
Loss on extinguishment of debt | — | — | — | ||||||||
(Loss) income before income taxes | (69.5 | ) | 78.3 | 8.8 | |||||||
Income tax (benefit) expense | (25.9 | ) | 29.9 | e | 4.0 | ||||||
Net income (loss) | $ | (43.6 | ) | $ | 48.4 | $ | 4.8 | ||||
12
UNAUDITED IKARIA PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
For the Three Months Ended December 31, 2013
(in millions)
Ikaria Three Months Ended December 31, 2013 | Pro Forma Adjustments | Pro Forma Ikaria Three Months Ended December 31, 2013 | |||||||||
Revenues: | |||||||||||
Net Sales | $ | 93.3 | $ | — | $ | 93.3 | |||||
Sales to related parties | 4.9 | — | 4.9 | ||||||||
Total revenues | 98.2 | — | 98.2 | ||||||||
Operating expenses: | |||||||||||
Cost of sales | 14.2 | — | 14.2 | ||||||||
Selling, general and administrative expenses | 35.1 | (2.5 | ) | d | 32.6 | ||||||
Research and development expenses | 25.2 | (9.2 | ) | b | 16.0 | ||||||
Amortization of acquired intangibles | — | 16.3 | c | 16.3 | |||||||
Merger transaction costs and expenses | — | — | — | ||||||||
Other operating (income) expense, net | 1.2 | — | 1.2 | ||||||||
Income from operations | 22.5 | (4.6 | ) | 17.9 | |||||||
Other (expense) income: | |||||||||||
Interest income | 0.2 | — | 0.2 | ||||||||
Interest expense | (23.1 | ) | — | (23.1 | ) | ||||||
Loss on extinguishment of debt | — | — | — | ||||||||
(Loss) income before income taxes | (0.4 | ) | (4.6 | ) | (5.0 | ) | |||||
Income tax (benefit) expense | 8.4 | (1.8 | ) | e | 6.6 | ||||||
Net income (loss) | $ | (8.8 | ) | $ | (2.8 | ) | $ | (11.6 | ) | ||
The unaudited pro forma condensed combined financial information has been prepared to reflect the acquisition of Ikaria by Compound Holdings II and the Bellerophon Spin-Out, and is provided for informational purposes only. The unaudited pro forma condensed combined statements of operations assume that the aforementioned transactions occurred on October 1, 2013. The unaudited pro forma condensed combined statements of income are not necessarily indicative of operating results that would have been achieved had these transactions occurred on October 1, 2013, nor is it intended to project the future financial results of Compound Holdings II after these transactions.
The unaudited pro forma condensed combined financial information has been prepared using certain assumptions, as described in the accompanying notes, which management believes are reasonable and do not reflect the cost of any integration activities, benefits from any synergies that may be derived from the transactions or revenue growth that may be anticipated. These unaudited pro forma condensed combined financial statements and related notes should be read in conjunction with the historical financial statements and related notes of Compound Holdings II and Ikaria incorporated by reference.
Historical Ikaria Pro Forma Adjustments
a. | The fair value of Compound Holdings II's inventory as of the date of its acquisition of Ikaria was $334.9 million. This fair value adjustment to inventory increased cost of sales during the fiscal year and three months ended December 31, 2014 by $287.7 million and $78.3 million, respectively, as the acquired inventory was sold. As there is no continuing |
13
impact, these increases has been removed from cost of sales in the unaudited pro forma condensed combined statements of operations for the fiscal year and three months ended December 31, 2014, respectively.
b. | Represents the removal of $1.1 million and $9.2 million of research and development expenses for the fiscal year ended December 31, 2014 and the three months ended December 31, 2013, respectively. These represent direct expenses that were incurred prior to the date of the transaction and were directly related to the research and development programs that were included in the Bellerophon Spin-Out. |
c. | The fair value of the identifiable intangible assets at the time of Compound Holdings II's acquisition of Ikaria was $913.0 million. For the purpose of determining additional pro forma amortization expense to be recorded in the unaudited pro forma condensed combined statements of income, the intangible assets were assumed to have useful lives of 15 years and were amortized on a straight-line basis. For the fiscal year ended December 31, 2014, an additional $7.6 million of amortization was added to reflect the amortization related to the period prior to the transaction (January 1, 2014—February 12, 2014). For the three months ended December 31, 2013, amortization of intangible assets was increased to $16.3 million. |
d. | Reflects the removal of $72.3 million and $2.5 million in non-recurring acquisition-related costs expensed by Compound Holdings II and Ikaria during the fiscal year ended December 31, 2014 and the three months ended December 31, 2013, respectively. |
e. | Reflects an increase to tax expense of $132.3 million and $29.9 million for the fiscal year ended December 31, 2014 and the three months ended December 31, 2014, respectively, and a decrease to tax expense of $1.8 million for the three months ended December 31, 2013, associated with the tax effects of the pro forma adjustments at the applicable statutory income tax rates. |
7. | Pro Forma Statements of Income Adjustments |
Cadence Acquisition Pro Forma Adjustments
a. | The fair value of the identifiable intangible asset, which relates to Cadence’s sole product, OFIRMEV, is $1.3 billion. For the purpose of determining additional pro forma amortization expense to be recorded in the unaudited pro forma condensed combined statements of income, the OFIRMEV intangible asset was assumed to have a useful life of eight years and was amortized on a straight-line basis. For the fiscal year ended September 26, 2014, historical Cadence patent amortization of $0.6 million was removed from cost of sales and $81.2 million of amortization was recorded for the OFIRMEV intangible asset. Additionally, the post-acquisition amortization expense recorded by Mallinckrodt in March 2014 of $4.8 million was removed from cost of sales. |
b. | The fair value of Cadence’s inventory as of the acquisition date was $21.0 million. This step-up in inventory increased cost of sales during the fiscal year ended September 26, 2014 by $12.1 million as the acquired inventory was sold. As there is no continuing impact, this $12.1 million increase has been removed from cost of sales in the unaudited pro forma condensed combined statements of income for the fiscal year ended September 26, 2014. |
c. | Shipping and handling costs of $1.3 million for the fiscal year ended September 26, 2014 have been reclassified in the unaudited pro forma condensed combined statements of income from cost of sales to selling, general and administrative expenses to conform with Mallinckrodt’s accounting policies. |
d. | In connection with the closing of the acquisition, Mallinckrodt terminated Cadence’s existing directors and officers (“D&O”) insurance policy and purchased a D&O insurance tail program providing six years of coverage for a net payment of $1.1 million, which will be amortized over the six-year coverage period. The pro forma adjustments for the fiscal year ended September 26, 2014 includes $0.2 million in amortization. |
e. | Reflects the removal of $17.6 million and $29.1 million in non-recurring acquisition-related costs expensed by Mallinckrodt and Cadence, respectively, during the fiscal year ended September 26, 2014. |
f. | In connection with the Cadence acquisition, Mallinckrodt entered into senior secured credit facilities consisting of a $1.3 billion term loan facility, with quarterly principal payments of 0.25% of the original principal amount of such term loan facility and the remainder due 2021, and a $250.0 million revolving credit facility due 2019, which was not utilized in the acquisition. Mallinckrodt incurred $32.4 million in deferred financing costs associated with the existing facilities. In addition, the term loan facility had an original issue discount of $3.3 million associated with it. Mallinckrodt also repaid Cadence’s existing debt in connection with the acquisition. The following pro forma adjustments were made in the unaudited pro forma condensed combined statements of income to reflect the impact of these transactions on interest expense: |
14
Year Ended September 26, 2014 | |||
Interest expense on the Facilities (1) | $ | 22.5 | |
Removal of Cadence historical interest expense | (2.3 | ) | |
Removal of historical interest expense booked on facilities for March 2014 | (1.3 | ) | |
Amortization of deferred financing costs | 2.5 | ||
Amortization of original issue discount | 0.2 | ||
$ | 21.6 | ||
(1) Interest expense on the variable rate term loan facility has been calculated using the interest rate in effect as of September 26, 2014, or 3.50%. If the interest rate in effect were to have increased 1/8 of a percent during the periods presented, the interest expense on the existing facilities would have been $23.3 million for the fiscal year ended September 26, 2014.
g. | Reflects a reduction to tax expense of $12.9 million for the fiscal year ended September 26, 2014 associated with the tax effects of the pro forma adjustments at the applicable statutory income tax rates. Also includes a reduction to tax expense of $17.2 million for the fiscal year ended September 26, 2014 due to the increase in interest expense as well as changes in the internal capital structure resulting from the acquisition. Also represents a reduction to tax expense of $8.4 million for the fiscal year ended September 26, 2014 associated with the recognition of the tax benefit from the removal of the valuation allowance on current year’s net operating losses that become realizable as a result of the acquisition. |
Questcor Acquisition Pro Forma Adjustments
h. | The fair value of the identifiable intangible asset, which relates to Questcor’s product, Acthar, is $5,343.3 million. For the purpose of determining additional pro forma amortization expense to be recorded in the unaudited pro forma condensed combined statements of income, the Acthar intangible asset was assumed to have a useful life of 18 years and was amortized on a straight-line basis. For the fiscal year ended September 26, 2014, historical Questcor amortization of $8.7 million was removed from cost of sales and $296.9 million of amortization was recorded for the Acthar intangible asset. Additionally, the post-acquisition amortization expense recorded by Mallinckrodt in August and September 2014 of $34.3 million was removed from cost of sales. |
i. | The fair value of Questcor’s inventory as of the acquisition date was $67.9 million. This step-up in inventory increased cost of sales during the fiscal year ended September 26, 2014 by $13.7 million as the acquired inventory was sold. As there is no continuing impact, this $13.7 million increase has been removed from cost of sales in the unaudited pro forma condensed combined statements of income for the fiscal year ended September 26, 2014. |
j. | The fair value of the identifiable intangible assets related to BioVectra, Inc., a wholly-owned subsidiary of Questcor, is $34.5 million. For the purpose of determining additional pro forma amortization expense to be recorded in the unaudited pro forma condensed combined statements of income, the BioVectra intangible asset was assumed to have a useful life of 12 years and was amortized on a straight-line basis. For the fiscal year ended September 26, 2014, historical Questcor amortization of $2.7 million was removed from selling, general and administrative expenses and $3.3 million of amortization was recorded for the BioVectra intangible asset. Additionally, the post-acquisition amortization expense recorded by Mallinckrodt in August and September 2014 of $0.6 million was removed from selling, general and administrative expenses. |
k. | Reflects the removal of $47.5 million and $44.2 million in non-recurring Questcor acquisition-related costs expensed by Mallinckrodt and Questcor, respectively, during the fiscal year ended September 26, 2014. |
l. | In connection with the acquisition of Questcor, certain subsidiaries of Mallinckrodt entered into $900.0 million eight-year 5.75% high-yield senior notes and a $700.0 million seven-year variable rate term loan facility as well as a $160.0 million three-year variable rate accounts receivable securitization facility (with an initial draw of $150 million). The term loan facility requires quarterly principal payments of 0.25% of the original principal amount of such term loan facility and had an original issue discount of $3.5 million. Additionally, certain subsidiaries of Mallinckrodt incurred approximately $38.0 million in deferred financing costs associated with the financing transactions. The following pro forma adjustments were made in the unaudited pro forma condensed combined statements of income to reflect the impact of these transactions on interest expense: |
15
Year Ended September 26, 2014 | |||
Senior notes interest | $ | 45.3 | |
Term loan interest (1) | 21.2 | ||
Accounts receivable securitization facility interest (1) | 1.2 | ||
Amortization of deferred financing costs | 4.4 | ||
Amortization of original issue discount | 0.4 | ||
$ | 72.5 | ||
(1) Interest expense on the variable rate term loan facility has been calculated using an estimated interest rate of 3.50%, and interest expense on the variable rate accounts receivable securitization facility has been calculated using an estimated interest rate of 0.96%. If the interest rate for each facility were to have increased 1/8 of a percent during the periods presented, the combined interest expense would have been $23.3 million for the fiscal year ended September 26, 2014.
m. | Reflects an increase to tax expense of $109.8 million for the fiscal year ended September 26, 2014 associated with the tax effects of the pro forma adjustments at the applicable statutory income tax rates. Also includes a reduction to tax expense of $73.0 million for the fiscal year ended September 26, 2014 due to the increase in interest expense as well as changes in the internal capital structure resulting from the acquisition. |
n. | Per the terms of our merger agreement with Questcor, Questcor shareholders received 54.0 million ordinary shares of Mallinckrodt and Questcor vested equity award holders received 1.5 million ordinary shares of Mallinckrodt. This represents a pro-rated portion of the additional shares issued for the period prior to acquisition. |
Ikaria Acquisition Pro Forma Adjustments
o. | The fair values of the identifiable intangible assets related to the INOMAX Developed Technology and the INOMAX Trademark, were estimated to be $1,660.0 million and $70.0 million, respectively. For the purpose of determining additional pro forma amortization expense to be recorded in the unaudited pro forma condensed combined statements of income, these intangible assets were assumed to have useful lives of 15 years and were amortized on a straight-line basis. For the fiscal year ended September 26, 2014 and the three months ended December 26, 2014, $110.7 million and $27.7 million, respectively, of amortization was recorded in costs of sales for the INOMAX Developed Technology intangible asset and $4.6 million and $1.2 million, respectively, of amortization was recorded in selling, general and administrative expenses for the INOMAX Trademark intangible asset. Additionally, for the fiscal year ended September 26, 2014 and the three months ended December 26, 2014, historical Ikaria amortization of $65.1 million and $16.4 million, respectively, was removed from selling, general and administrative expenses. |
p. | In connection with the acquisition of Ikaria, certain subsidiaries of Mallinckrodt entered into $700.0 million five-year 4.875% high-yield senior notes and $700.0 million ten-year 5.50% high-yield senior notes in addition to a $240.0 million draw on the existing revolver at 3.00%. Additionally, certain subsidiaries of Mallinckrodt incurred approximately $24.8 million in deferred financing costs associated with the financing transactions. Mallinckrodt also repaid Ikaria’s existing debt in connection with the acquisition. The following pro forma adjustments were made in the unaudited pro forma condensed combined statements of income to reflect the impact of these transactions on interest expense: |
Year Ended September 26, 2014 | Three Months Ended December 26, 2014 | ||||||
Removal of Ikaria historical interest expense | $ | (84.6 | ) | $ | (19.8 | ) | |
Five-year senior notes interest | 34.1 | 8.6 | |||||
Ten-year senior notes interest | 38.5 | 9.6 | |||||
Revolver interest (1) | 7.2 | 1.8 | |||||
Amortization of deferred financing costs | 3.3 | 0.8 | |||||
$ | (1.5 | ) | $ | 1.0 | |||
(1) Interest expense on the variable rate revolver has been calculated using an estimated interest rate of 3.00%. If the interest rate were to have increased 1/8 of a percent during the periods presented, the interest expense on the revolver would have been $7.5 million and $1.9 million for the fiscal year ended September 26, 2014 and the three months ended December 26, 2014, respectively.
16
q. | Reflects a reduction to tax expense of $19.2 million and $4.8 million for the fiscal year ended September 26, 2014 and the three months ended December 26, 2014, respectively, associated with the tax effects of the pro forma adjustments at the applicable statutory income tax rates. Also includes a reduction to tax expense of $5.7 million and $1.9 million for the fiscal year ended September 26, 2014 and the three months ended December 26, 2014, respectively, due to changes in the internal capital structure resulting from the acquisition. |
8. | Pro Forma Balance Sheet Adjustments |
As Cadence and Questcor were included within Mallinckrodt’s financial position as of December 26, 2014, no Cadence and Questcor acquisition-related pro forma adjustments were made to the historical balance sheet of Mallinckrodt.
Ikaria Acquisition Pro Forma Adjustments
a. | The following pro forma adjustments were made in the unaudited pro forma condensed combined balance sheet to reflect the anticipated impact of the acquisition and the assumed related financing transactions on cash and cash equivalents: |
Proceeds from senior notes | $ | 1,400.0 | |
Proceeds from revolver | 240.0 | ||
Payment for Ikaria outstanding shares | (1,137.9 | ) | |
Repayment of Ikaria third party debt | (1,162.1 | ) | |
Transaction fees and costs | (20.0 | ) | |
Deferred financing costs | (24.8 | ) | |
$ | (704.8 | ) | |
b. | Reflects the removal of $38.3 million remaining from the inventory fair value adjustment associated with the Compound Holdings, II acquisition of Ikaria as well as an increase of $26.7 million, which represents the estimated fair value adjustment to step-up Ikaria’s inventory to the estimated preliminary fair value of $40.0 million associated with Mallinckrodt's acquisition of Compound Holdings, II. This fair value adjustment in inventory will increase cost of sales as the acquired inventory is sold, which Mallinckrodt estimates will be within nine to twelve months from the date of acquisition, based on December 26, 2014 inventory levels. As there is no continuing impact, the effect on cost of sales from the inventory step-up is not included in the unaudited pro forma condensed combined statements of income. |
c. | Represents increases in current deferred tax assets of $4.4 million and non-current deferred tax liabilities of $382.2 million, primarily resulting from estimated fair value adjustments for the inventory and identifiable intangible assets. The estimate of deferred taxes from fair value adjustments was determined based on the excess of book basis from fair value accounting over the tax basis of the inventory and identifiable intangible assets at a 38.2% statutory tax rate. |
d. | Based on Mallinckrodt’s preliminary estimate, the excess of purchase price over net tangible and intangible assets acquired resulted in goodwill of approximately $741.1 million, which represents the assembled workforce, anticipated synergies and the tax-free status of the transaction. The goodwill is not deductible for U.S. income tax purposes. |
e. | Reflects the preliminary fair value of the identifiable intangible assets acquired of $1,970.0 million. The intangible assets include the rights to the technology, patents and trademark of Ikaria’s product, INOMAX, which is preliminarily expected to be amortized on a straight-line basis over a useful life of 15 years, and non-amortizable in-process research and development intangible assets. The fair values of the intangible assets were determined using the income approach, which is a valuation technique that provides an estimate of the fair value of the asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. |
f. | The following pro forma adjustments were made in the unaudited pro forma condensed combined balance sheet to reflect the impact of the anticipated financing transactions on other assets and liabilities. Anticipated impact of the following transactions on cash and cash equivalents is included within pro forma adjustment “a”. |
17
Balance Sheet Line Item | Amount | ||||
Removal of Ikaria historical deferred financing costs | Other assets | $ | (31.2 | ) | |
Repayment of Ikaria historical term loan | Current maturities of long-term debt | (69.8 | ) | ||
Repayment of Ikaria historical term loan | Long-term debt | (1,092.3 | ) | ||
Deferred financing costs | Other assets | 24.8 | |||
Senior notes - 2020 | Long-term debt | 700.0 | |||
Senior notes - 2025 | Long-term debt | 700.0 | |||
Revolver | Long-term debt | 240.0 | |||
g. | Ikaria’s historical equity accounts (the total of which is equal to its net book value) were eliminated as a result of the acquisition. |
h. | Estimated acquisition-related costs of $20.0 million are reflected as a reduction to retained earnings in the unaudited pro forma condensed combined balance sheet. The costs, which were expensed as incurred, include investment banking fees, filing fees, legal fees, accounting fees and other costs directly related to the acquisition. |
18